IMPella versus IABP REduces mortality in STEMI patients treated with primary PCI IN SEVERE and deep cardiogenic SHOCK. An international multicenter, randomized trial of the Impella cVAD (left ventricular assist) device versus Intra Aortic Balloon Counter Pulsation (IABP) therapy for acute ST-elevation myocardial infarction patients treated with primary PCI in severe and deep cardiogenic shock - IMPRESS in severe shock

Academisch Medisch Centrum0 个研究点目标入组 43 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1 Delay between onset of chest pain and PCI * 72 hours
•2 Cardiogenic shock defined as: systolic blood pressure * 90 mmHg for > 30 minutes or the need for supportive measures to maintain a systolic blood pressure * 90 mmHg.
•3 In order to ensure the most extremist category of cardiogenic shock, only patients who are already mechanically ventilated will be enrolled. For this trial we target a patient population with a Ph <7.3 and or lactate levels of around 6 mmol/L.

•1 Severe aorta-iliac arterial disease impeding placement of either devices
•2 Known severe cardiac aortic valvular disease
•3 Serious known concomitant disease with a life expectancy of less than one year

发起方